Bryn Pharma is a pharmaceutical company that offers nasal-based epinephrine for anaphylaxis.
Bryn Pharma has raised $26.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2023.
Bryn Pharma's investors include Capstone Partners, RezVen Partners, AllerFund, Chazen Capital Partners.
Bryn Pharma is headquartered in Beverly Hills, United States.
Bryn Pharma is a pharmaceutical company that offers nasal-based epinephrine for anaphylaxis.
Bryn Pharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bryn Pharma — Funding & Investors." VCBacked, May 10, 2023, https://www.vcbacked.co/company/bryn-pharma. Accessed October 14, 2026.
VCBacked. (2023). Bryn Pharma — Funding & Investors. Retrieved October 14, 2026, from https://www.vcbacked.co/company/bryn-pharma
{{cite web |title=Bryn Pharma — Funding & Investors |url=https://www.vcbacked.co/company/bryn-pharma |website=VCBacked |access-date=October 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated